SCHEMBL3014976

SCHEMBL3014976

COc1cc(Cc2csc(N3CCN(S(=O)(=O)c4ccccc4Cl)CC3)n2)cc(OC)c1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
TP53 P04637 2/20 0.41
ALDH1A1 P00352 6/20 0.40
LMNA P02545 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
CHRM4 P08173 2/20 0.40
HSD17B10 Q99714 2/20 0.40
TSHR P16473 1/20 0.40
MAPT P10636 4/20 0.39
MAPK1 P28482 1/20 0.39
RECQL P46063 2/20 0.39
USP2 O75604 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
GBA1 P04062 2/20 0.39
HTR7 P34969 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016794 0.93 TP53 (0.42) MEN1KMT2ATP53ALDH1A1LMNA
SCHEMBL3008949 0.91 HTR7 (0.44) KMT2ATP53ALDH1A1LMNASMN1; SMN2
SCHEMBL3009341 0.90 ALDH1A1 (0.40) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL3011886 0.90 CYP3A4 (0.48) TP53ALDH1A1LMNASMN1; SMN2TSHR
SCHEMBL3018943 0.90 CYP3A4 (0.44) TP53ALDH1A1LMNASMN1; SMN2TSHR
SCHEMBL3001787 0.89 MAPT (0.44) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL3018547 0.89 GAA (0.40) MEN1KMT2ATP53ALDH1A1LMNA
SCHEMBL3000530 0.89 MAPT (0.43) MEN1KMT2ATP53ALDH1A1LMNA
SCHEMBL3021361 0.88 CYP3A4 (0.53) MEN1KMT2ATP53ALDH1A1LMNA
SCHEMBL3012585 0.88 PKM (0.53) MEN1KMT2AALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MEN1 454/4885KMT2A 2680/4885TP53 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.